
-
Aptose Biosciences NasdaqCM:APTO Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Location: 251 Consumers Road, Toronto, ON, M2J 4R3, Canada | Website: https://www.aptose.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
5.167M
Cash
7.962M
Avg Qtr Burn
-9.294M
Short % of Float
10.64%
Insider Ownership
24.80%
Institutional Own.
11.51%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tuspetinib / Venetoclax / Azacitidine triplet Details Cancer, Leukemia, Acute myeloid leukemia | Phase 1/2 Data readout | |
Luxeptinib (CG-806) Details Cancer, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Acute myeloid leukemia | Phase 1/2 Update | |
Tuspetinib mono/combo w/ Venetoclax Details Cancer, Leukemia, Acute myeloid leukemia, Relapsed/refractory acute myeloid leukemia | Phase 1/2 Update | |
Tuspetinib (HM43239) & luxeptinib Details Acute myeloid leukemia, B-cell malignancies, Relapsed/refractory acute myeloid leukemia | Failed Discontinued | |
APTO-253 Details Cancer, Acute myeloid leukemia, Myelodysplastic syndrome | Failed Discontinued |